Today, Revvity, Inc., announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. Innovative, Easy-to-Use qPCR Workflow For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop progression of disease, and for SCID, immunoglobulin treatments combined with stem...